4,000 Johnson & Johnson $JNJ Shares Acquired by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 20.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 24,000 shares of the company’s stock after buying an additional 4,000 shares during the period. Johnson & Johnson accounts for about 3.9% of Sivik Global Healthcare LLC’s portfolio, making the stock its 3rd largest holding. Sivik Global Healthcare LLC’s holdings in Johnson & Johnson were worth $6,354,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of JNJ. Outlook Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $28,000. Matrix Trust Co boosted its position in Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the last quarter. Hyposwiss Advisors SA acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $42,000. Montgomery Financial Services LLC bought a new position in Johnson & Johnson in the second quarter valued at approximately $43,000. Finally, Polaris Financial Partners bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $56,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Adjusted third-quarter EPS was $2.59, above the $2.53 analyst consensus, while revenue increased 5.9% year over year to approximately $25.4 billion. Management also raised its 2026 guidance, including a reported-sales midpoint of $101.2 billion and adjusted EPS midpoint of $11.10. Johnson & Johnson reports Q3 2026 results and raises guidance
• Positive Sentiment: Innovative Medicine remained the primary growth driver. TREMFYA sales reportedly rose 68% to $2.4 billion, and new long-term Crohn’s disease data support the drug’s expansion potential. The company also highlighted its OTTAVA surgical system and other pipeline and portfolio initiatives. TREMFYA long-term Crohn’s disease data
• Positive Sentiment: Johnson & Johnson declared a quarterly dividend of $1.34 per share, reinforcing its income-investment appeal. Johnson & Johnson quarterly dividend announcement
• Neutral Sentiment: Management is leaning toward spinning out its hips-and-knees business, a move that could sharpen the company’s focus but also highlights ongoing pressure in the medical-device portfolio. J&J hips-and-knees business spinoff report
• Negative Sentiment: GAAP profitability fell sharply: reported net earnings were approximately $210 million, or $0.09 per share, as special charges tied to the proposed talc litigation resolution, the Firefly Bio acquisition and Sail Biomedicines collaboration overshadowed the adjusted earnings beat. Johnson & Johnson quarterly report analysis
• Negative Sentiment: MedTech grew only 2.5% operationally and underperformed internal expectations, particularly in Cardiovascular and Surgery outside the United States. Reports also cited weaker surgery revenue and Middle East-related pressure on medical-device sales. J&J earnings and MedTech performance
• Negative Sentiment: Investors may view the guidance increase as modest relative to elevated expectations, while planned drug deals are expected to weigh on 2027 earnings. That reduced the market’s enthusiasm for the current-quarter beat and contributed to the stock’s decline. Johnson & Johnson 2027 earnings warning

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Tuesday, September 29th. HSBC upped their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $287.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research report on Thursday, July 16th. Finally, TD Cowen boosted their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $276.22.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the business’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. The trade was a 50.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 87,569 shares of company stock valued at $23,064,544. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ traded down $16.34 during trading hours on Tuesday, hitting $247.39. The company had a trading volume of 6,586,227 shares, compared to its average volume of 7,940,307. The business has a fifty day moving average of $266.01 and a 200-day moving average of $249.31. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The firm has a market cap of $596.19 billion, a price-to-earnings ratio of 28.65, a PEG ratio of 2.65 and a beta of 0.21. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the prior year, the business earned $2.80 EPS. Johnson & Johnson’s quarterly revenue was up 5.9% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 11.18 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were paid a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.2%. Johnson & Johnson’s payout ratio is 62.11%.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.